Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aramchol Meglumine in Healthy Volunteers
NCT07251712Phase 1Recruiting
- Sponsor
- Galmed Pharmaceuticals
- Start
- Dec 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of aramchol in Nonalcoholic steatohepatitis (NASH) (2 arms), sponsored by Galmed Pharmaceuticals. Primary endpoints: Maximum observed peak concentration at 2 months, Time to reach maximum concentration at 2 months and 1 more. Started Dec 2025; status: recruiting.
02
Drugs
aramchol
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT07251712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07251712.